Blogs
Healthcare and Medtech Research Reports
Oct 16, 2026
Summary siRNA and ASOs are emerging as major RNA-based therapeutic platforms, enabling targeted disease treatment by silencing or modulating gene expression. siRNA holds a commercial advantage in revenue generation and dosing convenience. Marketed siRNA drugs generated approximately $4.2 billion in disclosed...
Read More...
Oct 01, 2026
UTR Therapeutics Inc. Announced U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14 On 29 September 2026, UTR Therapeutics Inc. announced that the U.S. FDA had granted Orphan Drug Designation to UTRxMYCN M1-14 for the treatment of soft tissue sarcoma, including rhabdomyosar...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper